Vaxcyte Inc (PCVX) - News Archive

: The forefront of pediatric immunization strategies is highlighted through Vaxcyte’s recent announcement regarding the advancement of its VAX-31 Infant Phase 2 Dose-Finding Study. With the initial participants now rece...

Vaxcyte Raises $1.5 Billion in Public Offering to Advance Vaccine InnovationVaxcyte, a clinical-stage vaccine innovation company, has announced the closing of a $1.5 billion public offering, including the full exercise...

IntroductionVaxcyte, Inc. a leading clinical-stage vaccine innovation company focused on developing high-fidelity vaccines to combat bacterial diseases, has recently declared the pricing of an underwritten public offeri...

Vaxcyte, Inc. Commences $1.0 Billion Common Stock and Pre-Funded Warrants OfferingSAN CARLOS, Calif. Sept. 03, 2024 - Vaxcyte, Inc. (Nasdaq: PCVX), a leading clinical-stage vaccine innovation company, announced today th...

In a significant advancement for public health, Vaxcyte has announced encouraging topline data from its Phase 1/2 clinical study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate designed for adults aged 5...

In an era where vaccine development is more vital than ever, Vaxcyte, Inc. a leader in clinical-stage vaccine innovation, is poised to redefine the landscape of pneumococcal disease prevention with its 31-valent pneumoc...

Vaxcyte Reports Q2 2024 Financial Results with Promising Developments in Vaccine ResearchIn its latest financial announcement, Vaxcyte, Inc. has released its second quarter results for 2024, detailing key aspects of its...

Vaxcyte, a leading biotechnology company focused on developing innovative vaccines, has recently announced the completion of enrollment for its Phase 2 clinical study evaluating VAX-24, a 24-valent pneumococcal conjugat...

Vaxcyte, Inc. Closes Highly Successful Public Offering, Raising $862.5 Million to Advance Breakthrough VaccinesSAN CARLOS, Calif., Feb. 02, 2024 - Vaxcyte, Inc., a pioneering vaccine innovation company, has recently con...

In a significant move towards advancing the fight against bacterial diseases, Vaxcyte, Inc. (Nasdaq: PCVX), a leading vaccine innovation company, has announced the pricing of its underwritten public offering of common s...

Vaxcyte, Inc., a clinical-stage vaccine innovation company specializing in high-fidelity vaccines against bacterial diseases, has recently announced the initiation of an underwritten public offering of its common stock...

Vaxcyte, a leading biotechnology company focused on developing next-generation vaccines, recently announced the completion of enrollment for its Phase 1/2 study evaluating VAX-31 as a potential preventive measure for In...

Vaxcyte Makes Significant Progress in the Development of a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) FranchiseVaxcyte, a leading biotechnology company, has recently announced important updates regardi...

In the latest development of its ambitious long-term strategy, Vaxcyte has exercised its option to obtain exclusive manufacturing and development rights through a crucial agreement with Sutro Biopharma. This move is set...

Vaxcyte and Lonza Join Forces to Expand Global Commercial Production of Pneumococcal Conjugate VaccinesAs the world continues to grapple with the devastating effects of the ongoing COVID-19 pandemic, another silent thre...